Amy Barnett, D.O. Titles and Appointments Clinical Assistant Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Amy Barnett, D.O., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hospital Medicine. She is currently on staff at Parkland Health and Hospital System. Originally from Tuscon, Dr. Barnett earned her bachelor's and master's degrees at the University of Arizona. She then completed her medical education at Midwestern University Arizona College of Medicine in Glendale. She completed internal medicine residency training at Baylor Scott and White in Temple. Certified by the American Board of Internal Medicine, Dr. Barnett joined the UT Southwestern faculty in 2018. Personal Note Dr. Barnett’s interests outside of medicine include family, art, and music. Education Other Post Graduate Training University of Arizona (2010) Graduate School University of Arizona (2010) Medical School Arizona College of Osteopathic Medicine at Midwestern University (2015) Residency Scott & White Memorial Hospital (2018), Internal Medicine Research Interest Cancer treatments Publications Featured Publications Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W, Oncotarget 2015 Feb 6 4 1954-66 Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK, Eur. J. Cancer 2012 Dec 48 18 3319-27 Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W, Clin. Cancer Res. 2012 Apr 18 8 2210-9 Radioprotection from radiation-induced lymphedema without tumor protection. Daley SK, Bernas MJ, Stea BD, Bracamonte F, McKenna M, Stejskal A, Hirleman ED, Witte MH, Lymphology 2010 Jun 43 2 48-58 MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D, BMC Cancer 2009 May 9 142 NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D, Oncogene 2008 Jul 27 30 4210-20 Results 1-6 of 6 1 Honors & Awards Silver Pin AwardOsteopathic Community Health Volunteer Award (2013) Sigma Sigma Phi - Rho ChapterOsteopathic National Honor and Service Fraternity (2012)
